Management of seizures in patients with primary mitochondrial diseases: consensus statement from the InterERNs Mitochondrial Working Group
Por:
Mancuso M, Papadopoulou MT, Ng YS, Ardissone A, Bellusci M, Bertini E, Di Vito L, Evangelista T, Fons-Estupina C, Hikmat O, Horvath R, Klopstock T, Kornblum C, Lamperti C, Licchetta L, Molnar MJ, Varhaug KN, O'Callaghan-Gordo M, Pressler RM, Schiff M, Servidei S, Szabo N, Gorman GS, Cross JH and Rahman S
Publicada:
1 jul 2024
Ahead of Print:
1 abr 2024
Resumen:
Background and purposePrimary mitochondrial diseases (PMDs) are common inborn errors of energy metabolism, with an estimated prevalence of one in 4300. These disorders typically affect tissues with high energy requirements, including heart, muscle and brain. Epilepsy may be the presenting feature of PMD, can be difficult to treat and often represents a poor prognostic feature. The aim of this study was to develop guidelines and consensus recommendations on safe medication use and seizure management in mitochondrial epilepsy. MethodsA panel of 24 experts in mitochondrial medicine, pharmacology and epilepsy management of adults and/or children and two patient representatives from seven countries was established. Experts were members of five different European Reference Networks, known as the Mito InterERN Working Group. A Delphi technique was used to allow the panellists to consider draft recommendations on safe medication use and seizure management in mitochondrial epilepsy, using two rounds with predetermined levels of agreement. ResultsA high level of consensus was reached regarding the safety of 14 out of all 25 drugs reviewed, resulting in endorsement of National Institute for Health and Care Excellence guidelines for seizure management, with some modifications. Exceptions including valproic acid in POLG disease, vigabatrin in patients with gamma-aminobutyric acid transaminase deficiency and topiramate in patients at risk for renal tubular acidosis were highlighted. ConclusionsThese consensus recommendations describe our intent to improve seizure control and reduce the risk of drug-related adverse events in individuals living with PMD-related epilepsy.
Filiaciones:
Mancuso M:
Department of Clinical and Experimental Medicine, Neurological Institute, University of Pisa, Pisa, Italy
Papadopoulou MT:
Department of Pediatric Clinical Epileptology, Sleep Disorders and Functional Neurology, University Hospital of Lyon, Member of the ERN EpiCARE, Lyon, France
Ng YS:
Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute AND National Institute for Health and Care Research (NIHR) Newcastle Biomedical Research Centre (BRC), Newcastle University, Newcastle upon Tyne, UK
NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
Ardissone A:
Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
Bellusci M:
Reference Center for Inherited Metabolic Disorders MetabERN, Mitochondrial Disorders Research Group (imas12), '12 de Octubre' University Hospital, Madrid, Spain
Bertini E:
Research Unit of Neuromuscular Disease, Translational Pediatrics and Clinical Genetics, Bambino Gesu' Children's Research Hospital, IRCCS, Rome, Italy
Di Vito L:
IRCCS Istituto delle Scienze Neurologiche di Bologna, Full Member of the European Reference Network for Rare and Complex Epilepsies (EpiCARE), Bologna, Italy
Evangelista T:
Department of Neuropathology, Functional Unit of Neuromuscular pathology and Department of Neuromyology, Institute of Myology, EURO-NMD coordination, Pitié-Salpêtrière Hospital, APHP Sorbonne University, Paris, France
Fons-Estupina C:
Epilepsy and Neurometabolics Units, Pediatric Neurology Department, Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Barcelona, Spain
Hikmat O:
Department of Paediatrics and Adolescent Medicine, Haukeland University Hospital, Bergen and Department of Clinical Medicine (K1), University of Bergen, Bergen, Norway
Horvath R:
Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
Klopstock T:
Department of Neurology, Friedrich-Baur-Institute, LMU University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
Kornblum C:
Department of Neurology, Section of Neuromuscular Diseases, University Hospital Bonn, Bonn, Germany
Lamperti C:
Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
Licchetta L:
IRCCS Istituto delle Scienze Neurologiche di Bologna, Full Member of the European Reference Network for Rare and Complex Epilepsies (EpiCARE), Bologna, Italy
Molnar MJ:
Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Budapest, Hungary
Varhaug KN:
Department of Neurology, Haukeland University Hospital, Bergen, Norway
O'Callaghan-Gordo M:
Epilepsy and Neurometabolics Units, Pediatric Neurology Department, Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Barcelona, Spain
Pressler RM:
UCL Great Ormond Street Institute of Child Health, London, UK
Great Ormond Street Hospital for Children, London, UK
Schiff M:
Reference Center for Mitochondrial Disorders (CARAMMEL) and Reference Center for Inborn Errors of Metabolism, Department of Pediatrics, Necker-Enfants-Malades Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris-Cité, MetabERN, Paris, France
INSERM UMRS_1163, Imagine Institute, Paris, France
Servidei S:
Dipartimento di Neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
Dipartimento Di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy
Szabo N:
Saint John's Hospital, Child Epilepsy Centre, Budapest, Hungary
Gorman GS:
Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute AND National Institute for Health and Care Research (NIHR) Newcastle Biomedical Research Centre (BRC), Newcastle University, Newcastle upon Tyne, UK
NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
Cross JH:
UCL Great Ormond Street Institute of Child Health, London, UK
Great Ormond Street Hospital for Children, London, UK
Rahman S:
UCL Great Ormond Street Institute of Child Health, London, UK
Great Ormond Street Hospital for Children, London, UK
Green Submitted, gold
|